Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
J Nutr Sci Vitaminol (Tokyo) ; 56(6): 335-46, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-21422702

RESUMEN

We previously found that thiamine mitigates metabolic disorders in spontaneously hypertensive rats, harboring defects in glucose and fatty acid metabolism. Mutation of thiamine transporter gene SLC19A2 is linked to type 2 diabetes mellitus. The current study extends our hypothesis that thiamine intervention may impact metabolic abnormalities in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, exhibiting obesity and metabolic disorders similar to human metabolic syndrome. Male OLETF rats (4 wk old) were given free access to water containing either 0.2% or 0% of thiamine for 21 and 51 wk. At the end of treatment, blood parameters and cardiac functions were analyzed. After sacrifice, organs weights, histological findings, and hepatic pyruvate dehydrogenase (PDH) activity in the liver were evaluated. Thiamine intervention averted obesity and prevented metabolic disorders in OLETF rats which accompanied mitigation of reduced lipid oxidation and increased hepatic PDH activity. Histological evaluation revealed that thiamine alleviated adipocyte hypertrophy, steatosis in the liver, heart, and skeletal muscle, sinusoidal fibrosis with formation of basement membranes (called pseudocapillarization) which accompanied significantly reduced expression of laminin ß1 and nidogen-1 mRNA, interstitial fibrosis in the heart and kidney, fatty degeneration in the pancreas, thickening of the basement membrane of the vasculature, and glomerulopathy and mononuclear cell infiltration in the kidney. Cardiac and renal functions were preserved in thiamine treatment. Thiamine has a potential to prevent obesity and metabolic disorders in OLETF rats.


Asunto(s)
Adipocitos/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Hígado/efectos de los fármacos , Enfermedades Metabólicas/prevención & control , Obesidad/prevención & control , Tiamina/uso terapéutico , Complejo Vitamínico B/uso terapéutico , Adipocitos/patología , Animales , Membrana Basal/efectos de los fármacos , Vasos Sanguíneos/efectos de los fármacos , Vasos Sanguíneos/patología , Fibrosis/tratamiento farmacológico , Riñón/efectos de los fármacos , Riñón/inmunología , Riñón/patología , Laminina/genética , Laminina/metabolismo , Leucocitos Mononucleares/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/patología , Miocardio/metabolismo , Miocardio/patología , Obesidad/metabolismo , Obesidad/patología , Oxidorreductasas/metabolismo , Páncreas/efectos de los fármacos , Páncreas/patología , ARN/metabolismo , Ratas , Ratas Endogámicas OLETF , Tiamina/farmacología , Complejo Vitamínico B/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA